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Lack of an effective small-animal model to study the Kaposi’s sar-
coma-associated herpesvirus (KSHV) infection in vivo has ham-
pered studies on the pathogenesis and transmission of KSHV.
The objective of our study was to determine whether the human-
ized BLT (bone marrow, liver, and thymus) mouse (hu-BLT) model
generated from NOD/SCID/IL2rγ mice can be a useful model for
studying KSHV infection. We have tested KSHV infection of hu-BLT
mice via various routes of infection, including oral and intravaginal
routes, to mimic natural routes of transmission, with recombinant
KSHV over a 1- or 3-mo period. Infection was determined by mea-
suring viral DNA, latent and lytic viral transcripts and antigens in
various tissues by PCR, in situ hybridization, and immunohisto-
chemical staining. KSHV DNA, as well as both latent and lytic viral
transcripts and proteins, were detected in various tissues, via var-
ious routes of infection. Using double-labeled immune-fluores-
cence confocal microscopy, we found that KSHV can establish
infection in human B cells and macrophages. Our results demon-
strate that KSHV can establish a robust infection in the hu-BLT
mice, via different routes of infection, including the oral mucosa
which is the most common natural route of infection. This hu-BLT
mouse not only will be a useful model for studying the pathogen-
esis of KSHV in vivo but can potentially be used to study the routes
and spread of viral infection in the infected host.
humanized mice | HHV-8 | mucosa transmission
The Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV),also known as the human herpesvirus 8, was first identified
from KS tissues in 1994 (1). It is the etiologic agent for KS and is
also associated with primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (2). More recently it was also
found to be associated with KSHV-associated inflammatory cy-
tokine syndrome (3). Although substantial progress has been
made in characterizing the virus, there are still many unanswered
questions such as how KSHV infection can lead to disease
manifestation and whether latent or lytic induction of KSHV are
associated with malignancies. One of the reasons is a lack of
a good small-animal model to study KSHV infection in vivo,
which has hampered studies on how KSHV infects, spreads, and
how it interacts with the host and ultimately leads to disease
pathogenesis. Moreover, currently there is no vaccine against
KSHV infection, and there is need for an effective animal model
to evaluate the efficacy of vaccines if they are developed and for
the testing of antiviral regimens.
An ideal model should have relatively short generation time,
reproduce rapidly, be inexpensive to maintain and house, and be
easy to manipulate. An example is a rodent model that can be
infected by KSHV effectively. Several small-rodent models
have been tested for KSHV infection. The models include
transplantation with both human KSHV-infected B lymphoma
cells and primary human peripheral blood mononuclear cells
in the SCID mouse (4), injection of KSHV into the human
skin engrafted or the transplant of the SCID mice (5, 6), or
injection of KSHV or KSHV-infected cells into the nonobese
diabetic (NOD)/SCID mice (7, 8). However, a better under-
standing of KSHV transmission, early events of viral infection,
its pathogenesis, its interaction with the host, and the develop-
ment of disease requires an in vivo model that supports natural
routes of viral infection, a long-term sustainable infection in-
volving both latent and lytic viral gene expression, and the in-
fection of target tissues and cells that reflect those of human
infection. The mouse models used so far have not been able to
achieve such goals.
Recently, a new generation of humanized mouse, the BLT
(bone marrow, liver, and thymus) mouse (hu-BLT) generated
from NOD/SCID/IL2rγ (NSG) mouse, has been shown to be an
excellent model for studying human viral infections (9). This
model has been shown to harbor a sustained high level of total
human immune cells and is also the only model that can generate
the human mucosal immune systems. In this study we found that
BLT mice can be infected by rKSHV.219 via intraperitoneal,
oral, and vaginal routes of inoculation. KSHV DNA, latent
protein LANA, and lytic protein K8.1 were readily detectable in
various tissues of the infected hu-BLT mice over 1- or 3-mo
periods after infection. We found that the virus can establish
both lytic and latent infections in human B cells and macro-
phages in the spleens, whereas infected cells in the skin were
predominantly latently infected macrophages. These results de-
monstrate that KSHV can establish both lytic and latent in-
fections efficiently in the hu-BLT mouse model and will be
useful for studying the pathogenesis and transmission of KSHV
in vivo.
Results
Infection of the hu-BLT Mice by KSHV. Before the inoculation by
KSHV the peripheral blood cells of the studied animals were
tested periodically by flow cytometry to monitor for the presence
of human leukocytes (hCD45+), mouse leukocytes (mCD45+),
human T cells (hCD45+ hCD3+), and human B cells (hCD45+
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hCD19+) at 2- or 4-wk intervals after reconstitution. The mice
used for inoculation by KSHV were found to have an average of
approximately 80% human CD45+ leukocytes among the total
leukocytes in peripheral blood cells at 12 wk after reconstitution
(Table 1). An example of one of the killed animals is shown in
Fig. 1A. Human MHC-1+ and human CD45+ cells were also
readily detectable in other tissues, such as spleens and skins. On
the average there were 50.7% ± 23.8% human CD45+ cells and
19.7% ± 7.8% mouse CD45+ in the spleens with six orally
infected animals analyzed as determined by flow cytometry. An
example of the flow data of the spleen of a typical BLT mouse is
shown in Fig. 1B, and an example of immunofluorescence staining
in the skin tissue is shown in Fig. 1C.
To determine whether hu-BLT mice can be infected by KSHV,
mice were divided into three groups, with each inoculated
with 2.5 × 105 infectious units of KSHV via three routes of in-
fection as shown in Table 1. Half of the i.p. and vaginal, and six
of nine orally infected animals were inoculated twice at 0 and 2
wk; the rest of the animals were inoculated four times at 0, 2, 6,
and 10 wk. The animals were killed to test for KSHV infection at
2 wk after the final inoculation. All animals inoculated with ei-
ther two or four doses of KSHV were found to be infected via
either routes of inoculation. KSHV DNA was found in various
tissues tested, such as lungs, spleens, lymph nodes, and skins
(Table 1). No viral DNA was detected in control mock-
infected animals.
The Human Cells in the Spleens of hu-BLT Mice Inoculated Orally by
KSHV Can Be Infected. Because the saliva and oral mucosal
infections have been shown to be the most likely routes of KSHV
transmission in humans, and B cells were shown to be a target of
infection, we first determined the effectiveness of infection of
spleen cells in animals inoculated orally by flow cytometry. Fig.
2A summarizes the levels of infection of six orally infected ani-
mals at 4 wk after infection: an average of 3.72% ± 1.65% of the
total spleen cells and 7.12% ± 0.88% of the total human cells
were infected, compared with only 0.29% ± 0.07% of the total
mouse cells in the spleens. An example of the flow cytometry
data of the spleen of one of the infected animals is shown in Fig.
2B. For this animal 5.27% of total spleen cells was found to be
infected by KSHV.219 and expressed GFP encoded by the virus
(Fig. 2B). Most infected cells were found to be human cells;
among them 6.61% were infected human cells, and 0.21% were
infected mouse cells.
To confirm that the cells infected by KSHV were expressing
viral transcripts, in situ hybridization (ISH) was carried out using
labeled viral RNA probes. The LANA antisense RNA probe was
used to detect viral LANA mRNA, and a mixture of two anti-
sense RNA probes of viral gB and K8.1 lytic genes were used to
detect lytic genes expression. Both latent and lytic gene expressions
were detected in spleens of mice that were inoculated via various
routes and doses of KSHV. Very clear hybridization signals
using the LANA-specific probe were detected in spleen tissue,
and an example of an orally infected animal is shown in Fig. 3
and Fig. S1, with LANA-specific (Fig. 3A, a) or with gB- and
K8.1-specific probes (Fig. 3A, c) at 12 wk after infection. Ex-
pression of both latent and lytic genes was found to be at com-
parable levels. No signal was detected using either LANA sense
probe (Fig. 3A, b) or gB and K8.1 sense probes (Fig. 3A, d) as
controls. These results imply that the infected spleen cells expressed
both latent and lytic genes.
The infected spleen cells were also found to be expressing viral
latent and lytic proteins by immunohistochemical staining (IHCS),
using antibodies specific for LANA and K8.1 proteins (Fig. 3B).
The anti-LANA antibody detected a typical punctate staining
of LANA in the nuclei of infected cells (Fig. 3B, a), with a mean of
approximately 23.4 cells/mm2 LANA-positive cells in infected
spleen tissues, and no staining was seen in the isotype control or
uninfected spleen tissues (Fig. 3B, b and c). Similarly, anti-K8.1
antibody showed a consistent membrane and cytoplasmic staining
in the lytically infected spleen cells (Fig. 3B, d; mean, 78.4 cells/
mm2), and no staining was found in uninfected spleen tissues
(Fig. 3B, e) or with isotype control (Fig. 3B, f). In contrast to
LANA, substantially more lytically infected cells expressing K8.1
antigen were detected. This suggests there are more lytically
infected cells than latently infected cells in the spleens of the
infected mice.
The Human Cells in the Skins of hu-BLT Mice Inoculated Orally by
KSHV Can Be Infected by KSHV. Endothelial cell is a primary tar-
get for KSHV and is involved in KS development. Because
KSHV DNA was found in the skin by PCR, we then tested the
skins of infected animals using both ISH and IHCS. An example
of the skin from an orally infected animal is shown in Fig. 4A and
Fig. S2. In contrast to the infected spleen, the gB- and K8.1-
specific probes revealed relatively few positive cells in the skin
tissues (Fig. 4A, c), and the LANA-specific probe detected many
more cells expressing a strong signal (Fig. 4A, a) than the lytic
gene probe. This result suggests that the majority of the KSHV-
infected cells in the skins were in the latent phase of infection.
To confirm the expression of viral latent and lytic proteins in
the skin tissues, IHCS using anti-LANA and anti-K8.1 was car-
ried out. As expected, LANA- and K8.1-expressing cells were
Table 1. Reconstitution and infection of the hu-BLT mice by KSHV
Inoculation route n
Inoculation times
(1 or 3 mo)





hu-leukocytes PCR positive (orf26)
Oral 9 2–4 times 80.8 (65.3–89.1) 39.5 59.8 Skin, spleen, lung
i.p. 4 2–4 times 80.5 (77.6–81.1) 58.5 39.0 Skin, spleen, liver, kidney,
lung, ileum, jejunum
Vaginal 4 2–4 times 80.2 (70.2–88.7) 70.5 26.1 Skin, lymph nodes, ileum
Control (PBS) 5 2 times 81.1 (76.5–86.4) 42.0 55.2 —
Fig. 1. Levels of human immune reconstitution in hu-BLT mice at 12 wk
after surgery. (A) PBLs were incubated with antibodies and then analyzed by
flow cytometry. Approximately 2 × 104 total live cells were evaluated for the
coexpression of either hCD45, mCD45, hCD3, or hCD19. (B) Splenic single-cell
suspensions were analyzed by multicolor flow cytometry. Approximately 5 ×
104 total live cells were evaluated for the coexpression of either hCD45,
mCD45, hCD3, or hCD19. (C) Skin tissues were analyzed by immunofluores-
cence using rabbit antibodies against hMHC-I (red) or hCD45 (red). DAPI
(blue) was used as counterstain. (Scale bars, 20 μm.)









detected in the skin tissues of the animals regardless of the route
and dosage of infection. Again, very few infected skin cells were
expressing K8.1 lytic antigen. An example of the skin tissue of an
orally infected mouse is shown in Fig. 4B and Fig. S2. A majority
of the skin cells from KSHV-infected cells showed LANA
staining (Fig. 4B, a), with a mean of 38.1 cells/mm2 LANA-
positive cells in infected skin tissues. In contrast, very few cells
were found to be expressing K8.1 (Fig. 4B, d; mean, 2.8 cells/
mm2). Additionally, no positive cell was found in the isotype
controls (Fig. 4B, b and e) or with control uninfected skin tissues
(Fig. 4B, c and f). Our results suggest that in contrast to the
infected spleen cells, most infected cells are in the latent phase
of infection.
Identification of KSHV-Infected Cell Types in the Spleens of Orally
Infected hu-BLT Mice by Multicolor Flow Cytometry and by Double-
Label Immunofluorescence Analysis. To identify the specific human
cell types that are infected by KSHV in the BLT mice, we first
analyzed the infected cells in the spleens by flow cytometry. Our
flow analyses showed that an average of 3.41% ± 1.67% of total
spleen cells of the six orally infected animals analyzed were
infected human leukocytes (hCD45+), and 3.07% ± 1.68% of all
analyzed spleen cells were infected human B cells (hCD45+
hCD19+) (Fig. 5A). No CD3+ T cells were found to be infected.
This suggests that most of the infected splenic leukocytes were in
fact human B cells. This was confirmed by analyzing the KSHV-
infected MHC-positive human cells. An average of 95.8% ±
1.4% of the infected human cells were human leukocytes, and an
average of 83.9% ± 6.8% were B cells (Fig. 5A). In addition, an
average of 39.9% ± 15.9% infected human cells were found to be
human CD31+ cells (Fig. 5A). This suggests that certain sub-
populations of the leukocytes can also express CD31, an endo-
thelial cell marker that has been reported to be expressed by
macrophages/monocytes and some subpopulation of lympho-
cytes (10). Because infected human T cells were undetectable,
thus the infected CD31+ cells could be macrophages/monocytes,
some subpopulation of B cells, and/or endothelial cells. An
example of the spleen of an orally infected animal is shown in
Fig. 5B. Through our flow analysis we concluded that the major
population of the infected human cells in spleens of the infected
BLT mice is B cells.
To confirm our flow analyses results and to identify the spe-
cific cell types, we analyzed the spleen tissues of animals infected
orally by confocal microscopy, using double-label immunofluo-
rescence (IFA) with anti-LANA or anti-K8.1 antibodies in
combination with antibodies against different human cell-surface
markers. As expected, LANA- and K8.1-expressing cells were
detected in the splenic tissues. We found that hMHC-1+,
hCD45+ (leukocytes), hCD20+ (B cells), hCD68+ (macrophages),
and hCD31+ (endothelial cells) were expressing LANA (Fig. 6A
and Fig. S3). In addition these same cell types were also found to
be K8.1 positive (Fig. 6B and Fig. S3). These results suggest that
the different human cell types found in the spleens can undergo
both latent and lytic infection. As for hCD31+ KSHV-infected
cells, they do not resemble endothelial cells morphologically (Fig.
6 A and B) but appear to be macrophage-like. To confirm that
endothelial cells can also be infected, we have tested an additional
endothelial cell marker, VEGFR2. However, results similar to
those seen with CD31 staining were obtained (Fig. S4). Thus, at
this point it is not clear whether there are substantial levels of
human endothelial cells present in the spleen tissues and whether
they could be infected by KSHV. Our results nevertheless suggest
that KSHV can establish both lytic and latent infection in
both human B cells and macrophages in the spleens of hu-BLT
mice infected orally. Infection of CD3+ human T cells was
undetectable.
Identification of KSHV-Infected Cell Types in the Skin Tissues of Orally
Infected hu-BLT Mice by Double-Label IFA Analysis. Double-label
IFA was also used to identify KSHV-infected cell types in skin
tissues of the orally infected animals. We found that human
MHC-1+, CD45+, CD68+, and CD31+ cells in the skin tissues
were also positive for LANA (Fig. 7 and Fig. S5). Interestingly,
in contrast to the spleen, infected human CD20+ B cells were not
found. Also in contrast to the spleen, majority of infected cells
were LANA-positive, and there were very few lytically infected
K8.1-expressing cells in the skin tissues analyzed, supporting our
immunohistochemistry analysis demonstrating that most of the
infected cells in the skin were expressing LANA antigen only
(Fig. 4B). Similar to the results with the spleen tissues, we cannot
conclude that the endothelial cells were present and infected in
the skin even though they expressed CD31 (Fig. 7). In summary,
the KSHV-infected skin cells seemed to be predominantly la-
tently infected human macrophages.
Discussion
Currently the hu-BLT mouse model has been used mostly to
study HIV-1 and a limited number of other viruses (9, 11–14).
Little is known whether this model can be used to study KSHV
infection, for which there is no good small-animal model to study
its infection and disease pathogenesis. We demonstrated in this
study that the hu-BLT mice can be infected via several known
Fig. 2. Determination of KSHV infection of the spleens of hu-BLT mice
infected by KSHV orally at 4 wk after infection by flow cytometry. (A) De-
termination of KSHV infection efficiencies of the spleen tissues at 4 wk after
infection (n = 6). (B) Splenic single-cell suspensions were measured by flow
cytometry. Approximately 3 × 104 total live cells were evaluated for the
coexpression of GFP and hMHC-I.
Fig. 3. Expression of KSHV latent and lytic
genes and proteins in the spleens of hu-BLT
mice infected orally. (A) KSHV latent and
lytic gene expression in the spleen of a hu-
BLT mouse by ISH at 12 wk after infection.
Probe for latent gene LANA was exposed for
8 d (a, LANA anti-sense probe; b, LANA sense
probe), and 16 d for the lytic gene probes (c,
K8.1 and gB antisense probes; d, K8.1 and gB
sense probes). (B) KSHV latent and lytic pro-
teins expression in the spleens at 4 wk after
infection. The spleens were from infected (a,
b, d, and e) or from PBS control mice (c and f). The splenic sections were incubated with antibodies to either LANA (a and c) or K8.1 (d and f) or mouse
IgG (b and e). (Scale bars, 100 μm in larger panels, 25 μm in Insets.)
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natural routes of infection, such as via oral and vaginal mucosal
routes. We also found that a large number of human B cells and
macrophages, which are known natural human host cells, were
infected. Our finding represents an important step forward to-
ward developing a robust small-animal model for KSHV in-
fection and disease pathogenesis.
It has been shown that KSHV DNA could be detected in
rhesus macaques inoculated with KSHV-infected PEL cells, but
it replicated to very low levels, and viral mRNA was not de-
tectable (15). In addition, Chang et al. (16) recently reported
that KSHV can establish persistent infection in marmosets and
could potentially serve as an animal model. However, given the
difficulty in working with nonhuman primates there is still a great
need to develop small-animal models, such as a rodent model,
that can be used to study KSHV infection and pathogenesis.
There have been several earlier attempts to use humanized
mouse models to study KSHV infection: the hu-PBL with
injected human peripheral blood lymphocytes (PBLs) (4), the
hu-HSCs mice engrafted with hematopoietic stem cells (HSCs)
(7), and the SCID-hu mice implanted with human liver and
thymus (6). However, these models have low levels and limited
functionality of the human immune cells, and the extent of in-
fection and gene expression was limited because of the limited
reconstituted human cell repertoire. The new generation of BLT
model uses the NSG parental mouse strain, which yielded more
severely immunocompromised mice to achieve far superior hu-
man cell engraftment (11). This is also the only mouse model
that can generate the human mucosal immune system and a hu-
man MHC restricted antigen-specific humoral and cellular re-
sponse (17).
In this study we found that animals inoculated with only two
doses of KSHV can be infected systemically by either oral or
vaginal routes of infection. The infected cells were found to be
mainly of human origins, but a few KSHV-infected cells were
found to be negative for human MHC class I in the spleen.
This observation of infected murine cells is consistent with
a previous study, which has shown that KSHV can infect the
mouse cells but that the infected cell numbers were low (8).
However, it is unlikely that mouse cells can support a sustainable
KSHV infection because it was shown by Austgen et al. (18) that
there are multiple postentry blocks to KSHV lytic replication
in murine cells, and infected murine cells were associated with
apoptotic cell death.
Our study here with the BLT mice showed that both latent
and lytic infection can be established in the infected animals
regardless of the route of infection. Interestingly, different levels
of lytic and latent infections can be established in different tis-
sues. Both lytic and latent infection can be observed in the
spleen. In contrast, in the skins most infected cells were latent
and expressed LANA. This difference in latent vs. lytic replica-
tion could reflect the tissue and cell type specificity, such that in
the spleen latent infection occurs in the spindle cells but lytic
replications are associating with B cells. However, in the skin
tissues, the positive cells are mainly macrophages. At this point it
is not clear whether the CD31+ and VEGFR2+ human cells are
in fact endothelial cells because even though they were stained
positive by endothelial cell markers they resemble macrophages
morphologically. It is possible that some macrophages could be
expressing endothelial cell markers in our infected animals. It
has been reported that transplanted human embryonic stem
cell-derived CD34+ cells can develop into human endothelial
cells in the liver of BLT mice (19); whether the human endo-
thelial cells are present in the skins and spleens of the BLT
mice and whether they can be infected by KSHV will need
further investigation.
Despite the robust infection of the hu-BLT mice, we were not
able to detect any humoral immune response against KSHV
when tested up to 3 mo after infection. This is not unexpected
because HIV-specific antibodies were delayed in the hu-BLT
model and can only be detected after 12 wk of infection (20).
Because the natural history of primary KSHV infection remains
unknown, and the humoral response against KSHV is known to
be nonrobust and transient (21), the KSHV serological responses
in this model need to be investigated further over a longer period
Fig. 4. KSHV latent and lytic genes and pro-
teins expression in the skins of hu-BLT mice
inoculated orally by KSHV at 12 wk after in-
fection. (A) KSHV latent and lytic gene ex-
pression in the skin of a hu-BLT mouse by ISH.
Thin sections of the spleen were hybridized
with 35S-labeled riboprobe specific for KSHV
LANA gene after 8 d exposure (a, LANA anti-
sense probe; b, LANA sense probe), and 16
d exposure for lytic genes (c, K8.1 and gB an-
tisense probes; d, K8.1 and gB sense probes).
(B) Detection of KSHV latent and lytic proteins
expression by IHCS in the skins. The skins were
collected from the infected (a, b, d, and e) or
control PBS mice (c and f). Skin sections were incubated with antibodies to either LANA (a and c) or K8.1 (d and f) or mouse IgG (b and e). Arrows
indicate LANA+ cells. (Scale bars, 100 μm in larger panels, 25 μm in Insets.)
Fig. 5. Identification of KSHV-infected cell types in the spleens of hu-BLT
mice at 4 wk after oral infection by flow cytometry. (A) KSHV infection ef-
ficiencies and infected cell populations in the spleen tissue at 4 wk after
infection (n = 6). (B) Splenic single-cell suspensions were measured. The
splenic single-cell suspensions were incubated with hCD45, hCD19, and
hCD31 mouse monoclonal antibodies and rabbit anti-GFP antibody. Ap-
proximately 3 × 104 total live cells were evaluated using a combination of
two antibodies.









of infection. In addition, none of our infected animals have de-
veloped any KS-like lesions, lymphomas, or any other specific
symptoms known to be related to KSHV infection. Although the
present study focused on establishing an in vivo system that
supports KSHV infection and the recapitulation of both latent
and lytic gene expression, whether this model can be used to
examine viral-related pathology remains to be established.
In conclusion, we report here that a humanized BLT mouse
model generated from NSG mice can support robust KSHV la-
tent and lytic infection, via transmission routes that occur during
natural infection in humans. Our data showed latent and lytic
viral transcripts, and viral protein expressions were detected in
various tissues, including spleen and skin tissues over a 1- or 3-
mo time course. Interestingly, mice were found to be infected via
several routes of infection tested, including via the oral mucosal
route. Furthermore, we found that KSHV can establish infection
in human B cells and macrophages in this model. This hu-BLT
mouse will be a useful model not only for studying the patho-
genesis of KSHV in vivo but can potentially be used to study the
routes and spread of the virus in the infected host.
Materials and Methods
Generation of hu-BLT Mice. Hu-BLT mice were generated by following the
previously published protocol (22). Six- to eight-week-old NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NOD/SCID/IL2rγnull, NSG) mice (The Jackson Laboratory) were
purchased and maintained in pathogen-free conditions at University of
Nebraska-Lincoln Life Sciences Annex. Human fetal livers and thymus tissues
were procured from Advanced Bioscience Resources. On the day of surgery,
mice received 12 cGy/g of mouse body weight with an RS200 X-ray irradiator
(Rad Source Technologies). The mice were transplanted with two pieces of
human fetal liver and one piece of thymic tissue fragments under the left
kidney capsules, followed by injection of 1.5–2.3 × 105 fetal liver-derived
CD34+ HSCs i.v. It took approximately 12–16 wk before the mice were ready
Fig. 6. Identification of KSHV-infected cell types in the
spleens of hu-BLT mice inoculated orally using double-label
IFA. (A) Identification of the cell types infected by KSHV
latently (LANA+) in the spleen tissues. (B) Identification of
the cells types infected by KSHV lytically (K8.1+) in the spleen
tissues. Double-labeled IFA was performed using mouse
antibodies to LANA (green) at 1:100 dilution or to K8.1 at
1:1,000 dilution (green), and rabbit monoclonal or polyclonal
antibodies to humanMHC-I, CD45, CD20, CD68, or CD31 (red).
DAPI (blue) was used as counterstain. (Scale bars, 10 μm.)
Fig. 7. Identification of the cell types infected by KSHV la-
tently in the skins of hu-BLT mice inoculated orally using
double-label IFA. Double-labeled IFA was performed using
mouse antibody to LANA (green) at 1:500 dilution, and rabbit
monoclonal or polyclonal antibodies to human MHC-I, CD45,
CD68, or CD31 (red). DAPI (blue) was used as counterstain.
(Scale bars, 10 μm.)
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to be challenged with KSHV, when the human leukocytes ratio to total
leukocytes was more than 50% in peripheral blood.
Viral Inoculations. Recombinant KSHV expressing GFP (rKSHV.219) (kindly
provided by Dr. J. Vieira, University of Washington, Seattle, WA) was used to
inoculate hu-BLT mice (23). A total of 2.5 × 105 infectious units of rKSHV.219
were used for each mouse; the animals were inoculated either i.p. (n = 4),
orally (n = 9), or through an intravaginal route (n = 4). In addition, five
control mice were inoculated with PBS either i.p. (n = 2), orally (n = 2), or
through an intravaginal route (n = 1). Half of the i.p. and i.v., and six of nine
oral-group mice, except the control, were inoculated twice at 0 and 2 wk.
The remaining animals were inoculated four times at 0, 2, 6, and 10 wk. All
studied animals were killed to test for KSHV infection at 2 wk after the
final inoculation.
Peripheral Blood and Tissue Analyses. PBLs were obtained before inoculation
and at various time points for flow cytometry analyses. Killed mice tissues
were dissected, fixed in SafeFix II (Fisher HealthCare) or 4% (vol/vol) para-
formaldehyde and then embedded in paraffin for analyses. Fresh tissues were
frozen and stored at −80 °C for DNA isolation. Fresh spleen tissues were col-
lected for subsequent flow analyses.
DNA Extraction and PCR Amplification from hu-BLT Mice Tissue for KSHV
Detection. DNA was extracted from mice tissue samples using the Pure-
gene Genomic DNA Purification Kit (Qiagen) according to the manufacturer’s
protocol. DNA was analyzed for KSHV DNA by PCR of the orf26 gene using
a previously described nested PCR protocol (24).
Immunohistochemical and Immunofluorescent Stainings. The IHCS used has
been described in detail previously (25). Briefly, slides were incubated in 3%
hydrogen peroxide for 30 min to block endogenous peroxidase activity if
HRP-conjugated antibody was used, followed by incubating in mouse IgG
blocking reagent (AffiniPure Fab Fragment Goat anti-mouse IgG; Jackson
ImmunoResearch Laboratories) for 2 h, then incubated for overnight at 4 °C
with mouse anti-LANA (1:1,000 dilution, kindly provided by Dr. Bala Chandran,
Rosalind Franklin University of Medicine and Science, Waukegan, IL) or with
mouse anti-K8.1 (1:1,000 dilution; 2A3, Advanced Biotechnologies) in blocking
reagent. After incubation with anti-mouse polymer–HRP-labeled secondary
antibody (Dako) or with anti-mouse MACH2 universal polymer–alkaline
phosphatase-labeled secondary antibody (Biocare Medical). The slides were
then incubated in DAB or Vulcan Fast Red (Biocare Medical) for color de-
velopment. The complete list of antibodies used can be found in SI Materials
and Methods. Confocal microscopy was used to identify the infected cell types.
Quantification of KSHV-Infected Cells by Immunohistochemistry. The frequency
of KSHV latently (LANA+) or lytically (K8.1+) infected cells was quantified
using a positive pixel count algorithm in Aperio’s Spectrum Plus analysis
program (version 9.1; Aperio ePathology Solutions) as described previously
(26). Briefly, immunochemically stained tissue sections were digitized using
Scanscope. The LANA- or K8.1-positive cells in digital slides were quantified
using a positive pixel count algorithm. The parameters of the algorithm
were tuned to match the markup image of LANA- or K8.1-positive staining
accurately over stain. Once the parameters were set, the algorithm was
applied automatically to all digital slides to measure the number of LANA- or
K8.1-positive cells (cells+/mm2). The mean values of LANA- or K8.1-positive
cells in the orally infected tissues (n = 9) were calculated.
Riboprobe Preparation and ISH. KSHV-specific probes were generated by
amplifying ∼700-bp LANA, K8.,1 and gB DNA fragments using LANA ex-
pression plasmid pSG-flag-LANA (kindly provided by Dr. Kenneth M. Kaye,
Harvard Medical School, Boston, MA), K8.1 expression plasmid pcDNA3.1
(+)-K8.1, and gB expression plasmid pcDNA3.1(-)-gB (initial plasmids both
kindly provided by Dr. Bala Chandran, Rosalind Franklin University of
Medicine and Science) as templates, respectively. Each fragment was
subcloned into a pGEM-T-easy vector (Promega). The resulting clones were
then linearized on either side of the insert with restriction enzyme to pro-
duce linear templates for runoff transcription of antisense and sense RNAs.
Radiolabeled riboprobes were synthesized by incorporating 35S-UTP using
the Promega transcription system, and ISH was conducted according to
published methods (25, 27).
Multicolor Flow Cytometry. Preparation of a single-cell suspension from
spleen using collagenase type IV (Sigma-Aldrich) has been described else-
where (28). After red blood cells were lysed, all cells were incubated in 80 μL
of the blocking reagent with 0.5 μg/106 cells of mouse FcγIII/II receptor
blocker (BD Biosciences-Pharmingen) for 10 min. Cell aliquots were in-
cubated for 30 min in the dark at 4 °C with fluorochrome-conjugated anti-
bodies, at 0.5 μg antibodies per 106 cells or according to the manufacturer’s
instructions. The complete list of antibodies used can be found in SI Mate-
rials and Methods. Stained cells were analyzed using a BD FACSAria III (BD
Biosciences) and FlowJo softward (version 7.6.4; Tree Star).
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SI Materials and Methods
For IFA the primary antibodies for human cell markers used were
either rabbitmonoclonal or polyclonal anti-MHC-I (1:200 dilution;
EP1395Y,Abcom), anti-CD45 (1:200 dilution;AbDSerotec), anti-
CD20 (1:100 dilution; EP459Y, Gene Tex), anti-CD68 (1:100 di-
lution; Abbiotec), anti-CD31 (1:250 dilution; EPR3094, Abcom),
anti-CD309/VEGFR2 (1:200 dilution; Thermo Scientific), and
anti-CD3 (1:200 dilution; SP7, Thermo Scientific). Primary anti-
bodies for viral antigens detection were mouse anti-LANA (1:100
dilution for spleen tissues and 1:500 dilution for skin tissues) or
mouse anti-K8.1 (1:1,000 dilution). Second antibodies were goat
anti-mouse or donkey anti-rabbit conjugated with Alexa Fluor 488
or 594 flourescence dyes (Life Technologies). DAPI was used as
nuclear counterstain.
For flow cytometry mouse monoclonal antibodies for cell sur-
facemarkers include anti-humanCD45-FITC (HI30, Biolegend) or
APC/Cy7 (HI30, Biolegend), anti-mouse CD45-APC (A20, Biol-
egend), anti-human CD3-PE (UCHT1, Biolegend), anti-human
CD19-PE/Cy5 (HIB19, Biolegend) or PE/Cy7 (HIB19, Biolegend),
anti-human MHC-I-APC (Tü149, Life Technologies), and anti-
human CD31-PE/Cy7 (WM59, Biolegend). Rabbit anti-GFP con-
jugated with Alexa Fluor 488 (Life Technologies) was used to
identify rKSHV.219KSHV.
Fig. S1. Expression of Kaposi’s sarcoma-associated herpesvirus (KSHV) latent (LANA) and lytic (K8.1) genes and proteins in the spleens of hu-BLT [humanized
BLT (bone marrow, liver, and thymus)] mice infected orally. KSHV latent (A, 35S-labeled LANA antisense probe) and lytic (C, 35S-labeled K8.1 and gB antisense
probes) gene expression in the spleen of a hu-BLT mouse by in situ hybridization (ISH) at 12 wk after infection. KSHV latent (B) and lytic (D) proteins expression
in the spleens at 4 wk after infection. (Scale bars, 100 μm in larger panels, 25 μm in Insets.)
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Fig. S2. Expression of KSHV latent (LANA) and lytic (K8.1) genes and proteins in the skins of hu-BLT mice infected orally. KSHV latent (A, 35S-labeled LANA
antisense probe) and lytic (C, 35S-labeled K8.1 and gB antisense probes) gene expression in the skin of a hu-BLT mouse by ISH at 12 wk after infection. KSHV latent
(B) and lytic (D) proteins expression in the spleens at 12 wk after infection. Arrows indicate LANA+ cells. (Scale bars, 100 μm in larger panels, 25 μm in Insets.)
Fig. S3. Identification of the cell types infected by KSHV latently (LANA) and lytically (K8.1) in the spleens of hu-BLT mice inoculated orally using double-label
immunofluorescence (IFA). Double-labeled IFA was performed using mouse antibodies to LANA (green) or to K8.1 (green), and rabbit monoclonal or polyclonal
antibodies to human MHC-I, CD45, CD20, CD68, or CD31 (red). DAPI (blue) was used as counterstain. Arrow indicates the infected CD31+ cell. (Scale bars, 10 μm.)
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Fig. S4. Identification of the endothelial cells infected by KSHV latently (LANA) in the spleens of hu-BLT mice inoculated orally using double-label IFA. Double-
labeled IFA was performed using mouse antibody to LANA (green), and polyclonal rabbit anti-human CD309/VEGFR2 (red). DAPI (blue) was used as coun-
terstain. Arrow indicates the double-stained VEGFR2+ cell. (Scale bars, 10 μm.)
Fig. S5. Identification of the cell types infected by KSHV latently (LANA) in the skins of hu-BLT mice inoculated orally using double-label IFA. Double-labeled
IFA was performed using mouse antibody to LANA (green), and rabbit monoclonal or polyclonal antibodies to human MHC-I, CD45, CD68, or CD31 (red). DAPI
(blue) was used as counterstain. Arrow indicates the infected CD31+ cell. (Scale bars, 10 μm.)
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